



Surveillance of HIV Drug Resistance in North America

October 18-20, 2004

Sheraton Suites
801 North Saint Asaph Street
Alexandra, VA 22314

Agenda

October 18, 2004			
7:30-9:30pm	Dinner Reception Sheraton Suites Hotel		
	Steering Committee members meet with speakers and moderators		
October 19, 2004		Moderator	Speakers/Discussants
7:30-8:30am	Breakfast		
8:00-8:20	Welcome & Introductions Introduction to the Forum for Collaborative HIV Research Presentation of Meeting Goals		<u>Veronica Miller</u> , FCHR <u>Diane Bennett</u> , CDC <u>Gayatri Jayaraman</u> / <u>Paul Sandstrom</u> , Health Canada
Session 1	HIV DR in Surveillance	<u>Veronica Miller</u> , FCHR	
8:20 – 9:00	HIV-1 Surveillance in Canada and the USA Examples of how surveillance has guided policy		<u>Eve Mokotoff</u> , US Council of State and Territorial Epidemiologists; <u>Gayatri Jayaraman</u> , Health Canada
9:00-10:00	Surveillance of HIV-1 DR in Canada and the USA Gaps in resources, knowledge, etc HIV DR Surveillance & Policy:		Brief overview presentations of issues and current programs: <u>Diane Bennett</u> , CDC <u>Gayatri Jayaraman</u> , <u>Paul Sandstrom</u> , Health Canada
10:00-10:15	Break		
10:15-11:30	Session 1 con't: What could be the public health actions resulting from HIV DR surveillance? What other information would help interpret HIV DR surveillance results to		Discussants: <u>Scott Hammer</u> , Columbia University; <u>Sally Blower</u> , UCLA, <u>Simon Frost</u> , UCSD;

	better guide policy?		ALL
Session 2	Surveillance Methods & Integration	<u>Melissa Hemmen</u> <u>Veronica Miller</u>	
11:30-12:30	Surveillance Issues for City, State and Provinces		Discussants: <u>David Barker</u> , CORE Center; <u>Susan Buskin</u> , Seattle/KC; <u>Nene Diallo</u> , Virginia DOH; <u>Colin Flynn</u> , MD DOH; <u>Robert Remis</u> , Toronto; <u>Kelly Voorhees</u> , Colorado DOH;
12:30-1:00	Moderated Open Discussion: sampling, integration into existing surveillance system, early vs. chronic infection, data dissemination, other issues		Discussants: <u>Alex Macalalad</u> , Harvard University, ALL
1:00 – 2:00	LUNCH		
Session 3	HIV DR Surveillance in Treated Patients	<u>Dan Kuritzkes</u>, <u>Brigham & Women's Hospital</u>	
2:00 – 2:30	Surveillance vs. special studies		Discussants: <u>Richard Harrigan</u> , UBC; <u>Viviana Simon</u> , Aaron Diamond; ALL
2:30-4:00	Public Health Actions and Policy		Discussant: <u>Scott Hammer</u> , Columbia University; ALL
4:00-5:00	Open Discussion		
Special Session for City & State DOH Representatives			
7-9:30 PM			
October 20, 2004			
7:30-8:30AM	Breakfast		
Session 4	Technology & Logistics	<u>Paul Sandstrom</u>, <u>Health Canada</u>	
8:30 – 10:00	Technology Issues What mutations, what assays? Specimen collection Integration into surveillance testing in private and public laboratories		<u>Gerardo Garcia-Lerma</u> , CDC; <u>Bob Shafer</u> , Stanford; <u>Lisa Frenkel</u> , U Washington <u>Rainer Ziermann</u> , Bayer Diagnostics; <u>Lee Bachelier</u> , Virco
10:00-10:15	Break		
Session 5	Data Collection and Database	<u>Simon Frost</u>, UCSD	

	Issues		
10:45-12:00	<u>Database Management</u> Duplication of data, etc <u>Analysis</u> Critical variables, Available data vs. “wish-list”, role of “special studies”		Overview presentation: “From genetic strings to analyzable data”, <u>Lyle McCormick</u> Discussants: <u>Sally Blower</u> , UCLA; <u>Bob Shafer</u> , Stanford
	Dissemination of results		ALL
12:00-1:00	LUNCH		
Session 6	Development of Recommendations	<u>Veronica Miller</u> , FCHR	
1:00-3:00 PM	Open moderated discussion based on previous sessions		All
3:00-4:00	Final Discussion & Next Steps		